L3VLUP
ProSign in

SUPN · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

SUPNJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • SUPN
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterSUPNJNJ
Q3 20203 holders, $49m30 holders, $26.2bn
Q4 20201 holders, $47m32 holders, $26.6bn
Q1 20211 holders, $46m31 holders, $25.3bn
Q2 20212 holders, $48m37 holders, $25.6bn
Q3 20213 holders, $40m40 holders, $24.1bn
Q4 20212 holders, $36m33 holders, $25.2bn
Q1 20224 holders, $62m35 holders, $28.2bn
Q2 20224 holders, $62m33 holders, $26.9bn
Q3 20225 holders, $75m36 holders, $25.4bn
Q4 20225 holders, $53m35 holders, $27.6bn
Q1 20233 holders, $55m42 holders, $24.5bn
Q2 20232 holders, $45m38 holders, $25.0bn
Q3 20231 holders, $40m37 holders, $18.9bn
Q4 20231 holders, $40m31 holders, $19.0bn
Q1 20243 holders, $91m32 holders, $19.7bn
Q2 20241 holders, $45m35 holders, $20.4bn
Q3 20243 holders, $61m28 holders, $22.3bn
Q4 20243 holders, $75m37 holders, $20.4bn
Q1 20253 holders, $54m32 holders, $20.5bn
Q2 20253 holders, $80m31 holders, $18.4bn
Q3 20256 holders, $244m32 holders, $23.7bn
Q4 20259 holders, $381m29 holders, $27.8bn
Q1 20268 holders, $399m34 holders, $35.6bn
Q2 20266 holders, $299m33 holders, $39.1bn
SUPN

Supernus Pharmaceuticals Inc

Holders
9
Reported value
$381m
Buyers
17
Sellers
14

Breadth +3 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
29
Reported value
$27.8bn
Buyers
13
Sellers
26

Breadth -13 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 34 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only SUPN (5)

Caxton Associates LLP, ExodusPoint Capital Management LP, PDT Partners LLC, Point72 Asset Management LP, Renaissance Technologies LLC

Only JNJ (25)

AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Rokos Capital Management LLP, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →